Abstract:BackgroundIn utero Zika virus (ZIKV) infection is a significant public health threat for infants as it can be vertically transmitted from mother to fetus, resulting in several health problems. Prolonged maternal viremia sometimes occurs in pregnant women with ZIKV infection. We hypothesize that mothers with prolonged viremia will be more likely to vertically transmit ZIKV to their fetuses. To evaluate this hypothesis, we developed a rhesus macaque pregnancy model of ZIKV infection, where some days have prolonged viremia (>10 days) and others have quickly cleared viremia (<10 days). Because the diagnosis of fetal ZIKV infection in newborns is challenging given the transient nature of ZIKV RNA viremia, we use infant-produced ZIKV-specific IgG as a marker of ZIKV vertical transmission. Here, we used a rhesus macaque model to define the association between longitudinal ZIKV-specific IgG antibody titers in infants and duration of maternal viremia.MethodsPregnant dams were inoculated in the first trimester, and their infants (n=8) were monitored for 12 months. ZIKV-specific IgG titers were measured in ZIKV-exposed infant serum samples using a whole virion ELISA at 1, 3, 6, 12, 18, 24, 30, and 36 months of age. Optical density was detected at 450nm on a SpectraMax M5e plate reader and IgG binding antibody curves were generated using R studio. Samples were below the limit of detection if they had EC90 values lower than the lowest serum dilution.ResultsOne of the eight infants displayed ZIKV-specific IgG titers at 12 months of age with undetectable ZIKV-specific IgG before 12 months of age, suggesting that these infants were infected in utero and produced their own ZIKV-specific IgG. This infant was born to a dam with a short duration of plasma viremia. The remaining seven infants displayed measurable ZIKV-specific IgG in the first 3 months of life and nothing after that point, indicating the presence of maternal antibody and no infant-specific antibody. There was no apparent association between maternal viremia duration and the presence of infant-produced ZIKV-specific IgG.ConclusionZIKV vertical transmission was confirmed in 1 of 8 pregnancies, and that case did not have a longer viremia compared to the other pregnancies. This indicates that either the rate of vertical transmission is not high in this macaque model, or that diagnostic methods for in utero infection with ZIKV are limited. We have additional pregnancies to complete antibody testing for in our cohort (10 additional pregnancies) and will learn more about this diagnostic method in these future studies.

Protective threshold of a potent neutralizing Zika virus monoclonal antibody in rhesus macaques

Potent Neutralizing Monoclonal Antibodies Against Ebola Virus Infection

A Single Injection of Human Neutralizing Antibody Protects Against Zika Virus Infection and Microcephaly in Developing Mouse Embryos.

A Recombinant Subunit Based Zika Virus Vaccine Is Efficacious in Non-human Primates

Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys

Structural basis of a potent human monoclonal antibody against Zika virus targeting a quaternary epitope.

A Zika Vaccine Targeting NS1 Protein Protects Immunocompetent Adult Mice in a Lethal Challenge Model

Predicting Efficacy of a Purified Inactivated Zika Virus Vaccine in Flavivirus-Naïve Humans Using an Immunological Correlate of Protection in Non-Human Primates

Zika-specific neutralizing antibodies targeting inter-dimer envelope epitopes

Molecular Determinants of Human Neutralizing Antibodies Isolated from a Patient Infected with Zika Virus.

Cathelicidin-Derived Antimicrobial Peptides Inhibit Zika Virus Through Direct Inactivation and Interferon Pathway.

Critical Neutralizing Fragment Of Zika Virus Ediii Elicits Cross-Neutralization And Protection Against Divergent Zika Viruses

Two immunogenic recombinant protein vaccine candidates showed disparate protective efficacy against Zika virus infection in rhesus macaques

Neutralization Mechanism of a Highly Potent Antibody Against Zika Virus

Neutralization of Zika Virus by Germline-Like Human Monoclonal Antibodies Targeting Cryptic Epitopes on Envelope Domain III

Antibodies targeting epitopes on the cell-surface form of NS1 protect against Zika virus infection during pregnancy

Structural Basis of Zika Virus Specific Neutralization in Subsequent Flavivirus Infections

Protective efficacy of a Zika purified inactivated virus vaccine candidate during pregnancy in marmosets

A Human Antibody Against Zika Virus Crosslinks the E Protein to Prevent Infection

Monoclonal Antibodies against Zika Virus NS1 Protein Confer Protection via Fc γ Receptor-Dependent and -Independent Pathways

Short-Lived Zika Virus-Specific Antibodies in Infants: Findings from a Translational Macaque Model